3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
11
Neoplasm Metastasis
2
Endometrial Neoplasms
2
Colorectal Neoplasms
2
Solid Tumors
1
PIK3CA-Mutated Cancers
1
Neoplasms
1
Metastatic Castration-Resistant Prostate Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
fludarabine
4
Cyclophosphamide
4
fludarabine phosphate
3
Melphalan
3
pembrolizumab
2
obinutuzumab
2
blinatumomab
2
Rituximab
2
Radiotherapy
2
Lenalidomide
2
Capecitabine
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tislelizumab
1
tisagenlecleucel
1
thymoglobulin
1
tetrathiomolybdate
1
talquetamab
1
sacituzumab govitecan
1
palbociclib
1
nilotinib
1
isatuximab
1
avelumab
1
atezolizumab
1
acalabrutinib
1
Whole-Body Irradiation
1
Trastuzumab
1
Sirolimus
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neoplasm, Residual
×
inavolisib
×
90 days
×
Clear all
No trials found.